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Summing up, we present a previously
unreported mutation in exon 18 of the
c-KIT gene, contributing to a phenotype
of CM with sMCAS and a tendency
to incomplete resolution in adulthood.
We also identified an additional muta-
tion in exon 18 of the c-KIT gene
possibly associated with a more severe
phenotype.
The study has been approved by the
institutional ethics committee (Ethics
committee of the Medical University of
Vienna, approval number 901/2009).
Informed written consent was given by
all patients and their parents, respec-
tively. The study adhered to the
Declaration of Helsinki principles.
DNA from formalin-fixed paraffin-
embedded (FFPE) skin biopsies were
extracted using the DNAeasy Blood
and Tissue Kit (Qiagen, Valencia, CA)
after deparaffinization. For DNA extrac-
tion from blood, 200ml of blood was
used with the Qiagen DNA Blood and
Tissue Kit according to the manufac-
turer’s instructions. To examine c-Kit
exons 8, 9, 11, 13, 17, and 18 for
mutations in CM samples, FFPE-derived
DNA was further amplified using nested
PCR with a multiplex preamplification
step to compensate for limited DNA
yields from FFPE extraction. Preamplifica-
tion was performed in a 25-ml volume
with the Ampli Taq Gold 360 DNA Poly-
merase Kit (Applied Biosystems, Vienna,
Austria) and at least 25ng of DNA tem-
plate. As a second step, amplification
using nested primer pairs (see online
repository for table) was performed with
the Ampli Taq Gold 360 DNA Polymer-
ase Kit and 1ml of the preamplification
product. For amplification steps for blood-
derived DNA, the same protocol and
primers were used as for FFPE material.
After PCR amplification, appropriate exon
lengths were controlled on a 1.5% agar-
ose gel, and PCR products were subse-
quently sequenced using an ABI 3000
capillary sequencer (Applied Biosystems).
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TO THE EDITOR
In the past few years, intravital imaging
has been developing, especially that
using a multiphoton confocal technique
(Li et al., 2012). Such a technique is quite
a useful tool for understanding cellular or
molecular dynamic events in vivo. How-
ever, this technique requires labeling of
fluorescence, and the fluorescence is
usually labeled genetically, by trans-
fection, or by direct linking. In the case
of human cells, there is the concern that
these treatments affect the functional
capability of the treated cells. A method
of intravital imaging that does not have
biological influences is needed.
Recently, we developed a far-red
luminescent probe as a convenient
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analytical tool for evaluating mAb loca-
lization in a living body (Wu et al.,
2009). We conjugated a far-red
fluorescent indocyanine derivative to
biotinylated Cypridina luciferase. This
conjugate, which is linked to a mAb
against a specific antigen, enabled us
to obtain high-resolution microscopic
images of live, specific antigen-expres-
sing cells without an external light
source, and to monitor the accumula-
tion of the probe in mice.
In this paper, we used this probe to
detect human cells intravitally in human
skin lesions of graft-versus-host disease
(GVHD) model mice.
This far-red luminescent probe for
human CD45 (anti-human CD45 Ab;
BD Biosciences, San Diego, CA) and
CD4 (anti-human CD4; BioLegend,
Tokyo, Japan), was generated as we
reported previously (Wu et al., 2009).
Full-thickness human skin from a
volunteer was grafted to the backs
of immunocompromised NOD/Shi-scid,
IL-2Rnull (NOG) mice that lacked T, B,
and natural killer cells, allowing a
tolerance to human cells (Ito et al.,
2002). After confirming engraft-
ment 14 days after skin graft, 1 107
human peripheral blood mononuclear
cells (PBMCs) from other volunteers
were injected intravenously (i.v.) into
the skin-grafted mice. For in vivo
imaging, far-red luminescent probes
were injected into the mice i.v. 5 days
after human PBMC injection. To obtain
the bioluminescence images, the mice
were given i.v. injections of Cypridina
luciferin 24h before imaging. Biolumines-
cence imaging was performed by a
Photon Imager (Biospace Lab, Paris,
France) equipped with an intensified
charge-coupled device camera after
luciferin injection with 30-s exposure
(detailed materials and methods are pro-
vided in the Supplementary Data online).
First, we observed human PBMCs
incubated with these probes in vitro
using a charge-coupled device imaging
system in a 96-well plate. We deter-
mined a light intensity threshold to
indicate a positive result (Figure 1a).
Next, we injected human PBMCs that
had been incubated with these probes
in vitro. Two hours after injection, con-
canavalin A (ConA) (20 or 2 mg kg1)
was applied intradermally in the ears of
the same mice to induce an inflamma-
tory response. As shown in Figure 1b,
higher bioluminescence intensity was
detected in the 20 mg kg1 ears (arrow-
head) than in the 2 mg kg1 ears
(arrow). In addition, the density of infil-
trated human CD45þ cells in the
20 mg kg1 ears (Figure 1d) was signifi-
cantly higher than that in the 2 mg kg1
ears (Figure 1c). These data clearly
indicate that the accumulation of
labeled cells tends to correlate with
bioluminescence intensity. Although
the bioluminescence signal disappeared
within 30 min, another luciferin applica-
tion elicited the signal even 2 days later
(Supplementary Figure S1 online). These
data show that the far-red biolumines-
cent probe is useful for intravital mon-
itoring of human cells in mice.
Next, to evaluate the usefulness of
this probe in detecting human cell
behavior in mice, we examined the
distribution of human PBMCs that were
injected into human skin lesions of
GVHD model mice (Figure 2a) using
this probe with anti-human CD45 Ab.
Bioluminescence images showing a
high signal were specifically detected
in the skin-grafted areas (Figure 2b).
The NOG mice in our experiment are
severely immunocompromised, and
lymph nodes could hardly be identified
(Kambe et al., 2004). Therefore, human
lymphocyte accumulation was observed
only in the human skin–grafted area. Six
days after human leukocyte injection,
there were no manifestations and no
human cells were detected in other skin
using human CD45 staining (data not
shown). Immunostaining confirmed that
numerous infiltrating human CD45þ
cells were accumulated in the skin graft
(Figure 2c). A few murine dendritic cells
(DCs) (murine CD11cþ ) were detected
in the upper dermis of the GVHD
area, whereas numerous human T cells
(human CD3þ ) were infiltrated in the
same area (Supplementary Figure S2
online). In contrast, there was a
certain number of human DCs (human
CD11cþ ) in the GVHD area, and some
human DCs seemed to locate closely to
human T cells (Supplementary Figure S3
Luciferin(–) Luciferin(+)
Figure 1. Bioluminescence images of a far-red luminescent probe in vitro and in vivo. (a) Human
peripheral blood mononuclear cells (PBMCs) incubated with the probes in vitro were observed using a
charge-coupled device imaging system in a 96-well plate. The detected light intensity of the probe with
luciferin was high. (b) Human PBMCs that were incubated with these probes in vitro were injected into
NOG mice. Two hours after injection, 2 mg kg 1 (arrow) or 20 mg kg 1 (arrowhead) of ConA was
injected intradermally in the ears of the same mouse. Next, luciferin (200ml) was injected after 1 day.
Bioluminescence images showed the probes to be visible in the ConA-injected ear, suggesting that human
CD45þ PBMCs had accumulated there. Immunostaining showed numerous infiltrating human CD45þ
cells in treated ears, and the density of infiltrated human CD45þ cells in the 20 mg kg1 ear (d) was
significantly higher than in the 2 mg kg 1 ear (c).
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online). From these data, it is possible
that human T cells and human DCs
interact in the skin lesion of this GVHD
model. Probes with anti-human CD4 or
CD8 were also able to demonstrate the
gathering of cells in the skin-grafted
areas, confirming the infiltration of both
cell types into the skin-grafted areas
(Supplementary Figures S4 and S5
online). These data indicate that the
far-red bioluminescent protein probes
enable the monitoring of human cells
temporarily in human GVHD skin
lesions on model mice.
Fluorescence labeling is an alternative
method for detecting human cells; how-
ever, labeling treatment might influence
biological function. Indeed, modification
of a specific gene often affects the expres-
sion of other genes or proteins. In
antigen–antibody-based fluorescence
labeling, signal induction or inhibitory
effect by antigen-antibody binding are
concerns. Therefore, the choice of anti-
body is crucial in generating probes. The
antibodies that were used in our study
have been confirmed to have little effect
on cellular function. Furthermore, our
probe enables serial intravital observation.
Because of the similarity of luciferin to
albumin, it does not cause an immune
response and the toxicity appears low.
However, its usefulness in antibody-based
labeling is limited, because it is difficult to
separate multiple bioluminescence sig-
nals, whereas fluorescence provides sev-
eral separate signals. In addition, using
multiphoton intravital imaging, it is now
possible to perform dynamic, multidimen-
sional imaging to track cell populations at
the single-cell level in vivo (Li et al.,
2012). For example, dynamic processes
in skin transplant rejection in mice were
visualized by multiphoton intravital imag-
ing (Celli et al., 2011). For biolumi-
nescence signals, it is difficult to detect
cellular-level imaging at present. If these
limitations are overcome, biolumines-
cence imaging promises to be a power-
ful tool for revealing biological dynamics.
Furthermore, our data showed that
human T cells do not necessarily require
lymphoid organs to expand in the mur-
ine host, and that they expand in skin. In
addition, human T cells associate pre-
dominantly with human, rather than
murine, DCs, suggesting that DCs of
recipient origin contribute to the expan-
sion of T cells in this GVHD model.
In conclusion, our far-red biolumines-
cent probe promises to enable the
analysis of human cell localization in
model mice without modification of the
cellular function.
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Figure 2. Visualization of human cells in graft-versus-host disease (GVHD) lesion using a far-red
luminescent probe. (a) The human skin graft on a NOG mouse. (b) Ten million peripheral blood
mononuclear cells in 200ml of phosphate-buffered saline per mouse was injected i.v. For in vivo imaging, a
0.2-ml solution containing anti-CD45 antibodies was injected into the mice i.v. 24 h before imaging. Each
experiment was carried out twice. To obtain the bioluminescence image, the mice were given injections of
200-ml Cypridina luciferin just before imaging. Bioluminescence imaging was performed by Photon Imager
equipped with an intensified charge-coupled device camera after luciferin injection into the GVHD model
mice. Bioluminescence images were specifically detected in skin-grafted areas. (c) Skin lesion of GVHD
model mice stained with FITC anti-human CD45 Ab. The immunostaining confirms that numerous
infiltrating human CD45þ cells have accumulated in the skin graft.
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